Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 3/20 | 0.53 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.53 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.37 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.37 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 2/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.36 |
| ▸ | CTRC | Q99895 | 1/20 | 0.35 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7826899 | 0.80 | HDAC6 (0.62) | HDAC2HDAC8HDAC6GSK3AGSK3B | |
| SCHEMBL8066345 | 0.75 | HDAC8 (0.61) | HDAC2HDAC8HDAC6GSK3AGSK3B | |
| SCHEMBL21563554 | 0.75 | HDAC8 (0.61) | HDAC2HDAC8HDAC6GSK3AGSK3B | |
| SCHEMBL16700836 | 0.75 | HDAC8 (0.58) | HDAC2HDAC8HDAC6GSK3AGSK3B | |
| SCHEMBL2079073 | 0.75 | HDAC8 (0.61) | HDAC2HDAC8HDAC6GSK3AGSK3B | |
| SCHEMBL23058167 | 0.75 | HDAC2 (0.58) | HDAC2HDAC8HDAC6GSK3AGSK3B | |
| SCHEMBL5075725 | 0.73 | HDAC8 (0.79) | HDAC2HDAC8HDAC6 | |
| SCHEMBL23513227 | 0.73 | HDAC8 (0.59) | HDAC2HDAC8HDAC6GSK3AGSK3B | |
| SCHEMBL6007674 | 0.73 | HDAC8 (0.62) | HDAC2HDAC8HDAC6GSK3AGSK3B | |
| SCHEMBL23496820 | 0.73 | HDAC8 (0.59) | HDAC2HDAC8HDAC6GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240059649-A1 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2024-02-22 | — | — | US | disclosed |
| US-20210395194-A1 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-20210395194-A1 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| US-10961187-B2 | Substituted N-acetyl-L-cysteine derivatives and related compounds | PROMENTIS PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-10961187-B2 | Substituted N-acetyl-L-cysteine derivatives and related compounds | PROMENTIS PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| EP-3674297-A1 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS | Promentis Pharmaceuticals, Inc. (US) | 2020-07-01 | — | — | EP | disclosed |
| EP-3066089-B1 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS | PROMENTIS PHARM INC (US) | 2019-11-06 | — | — | EP | disclosed |
| EP-3066089-B1 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS | PROMENTIS PHARM INC (US) | 2019-11-06 | — | — | EP | disclosed |
| US-20190315683-A1 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190315683-A1 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| US-20170183303-A1 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170183303-A1 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170183303-A1 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-9630937-B2 | Substituted N-acetyl-L-cysteine derivatives and related compounds | PROMENTIS PHARMACEUTICALS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630937-B2 | Substituted N-acetyl-L-cysteine derivatives and related compounds | PROMENTIS PHARMACEUTICALS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-9630937-B2 | Substituted N-acetyl-L-cysteine derivatives and related compounds | PROMENTIS PHARMACEUTICALS, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| WO-2015070034-A1 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. (US) | 2015-05-14 | — | — | WO | disclosed |
| US-20150133470-A1 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. | 2015-05-14 | — | — | US | disclosed |
| US-20150133470-A1 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. | 2015-05-14 | — | — | US | disclosed |
| US-20150133470-A1 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS | PROMENTIS PHARMACEUTICALS, INC. | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210395194-A1 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS | ACAT1, NLN, GOT2 | HDAC2 340/4885HDAC8 725/4885HDAC6 124/4885 |
| US-20240059649-A1 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS | ACAT1, NLN, GOT2 | HDAC2 340/4885HDAC8 725/4885HDAC6 124/4885 |
| US-20170183303-A1 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS | ACAT1, NLN, GOT2 | HDAC2 340/4885HDAC8 725/4885HDAC6 124/4885 |
| US-20150133470-A1 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS | ACAT1, NLN, GOT2 | HDAC2 340/4885HDAC8 725/4885HDAC6 124/4885 |
| US-10961187-B2 | Substituted N-acetyl-L-cysteine derivatives and related compounds | ACAT1, NLN, GOT2 | HDAC2 340/4885HDAC8 725/4885HDAC6 124/4885 |
| US-20190315683-A1 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS | ACAT1, NLN, GOT2 | HDAC2 340/4885HDAC8 725/4885HDAC6 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.